



# **Structure and Interactions of the C-terminal Domain of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2)**

**By**

**Zhihe Kuang, B.Sc, M.Sc**

**A Thesis submitted to The University of Adelaide, South Australia  
in fulfilment of the requirements for the Degree of  
Doctor of Philosophy**



**School of Molecular & Biomedical Science  
The University of Adelaide  
Adelaide, South Australia  
October, 2006**

# Table of Contents

Table of Contents .....	1
Acknowledgements .....	i
Statement of Originality .....	ii
Abstract .....	iii
Abbreviations .....	v
List of Figures .....	vii
List of Tables.....	x
List of Publications.....	xi

<b>Chapter 1</b> Introduction and Literature Review .....	1
1.1 An Introduction to the IGF System .....	1
1.1.1 Components of the IGF system: overview .....	1
1.1.2 Molecular interactions of the IGF system .....	4
1.1.3 Expression and regulation of IGFs and IGFBPs .....	5
1.1.4 Biological actions of IGFs.....	6
1.1.5 Biological functions of IGFBPs .....	7
1.1.6 Implications of the IGF system in health and diseases.....	8
1.2 Biological Actions of IGFBP-2 .....	10
1.2.1 IGF-dependent and -independent actions.....	10
1.2.2 Roles of IGFBP-2 in Cancer.....	11
1.3 Structure of the IGFs, and receptor and IGFBP binding determinants .....	11
1.3.1 Structure of IGFs .....	11
1.3.2 The IGF-1R, IGF-2R, IR-A and IR-B binding residues of IGFs .....	15
1.3.3 The IGFBP binding residues of IGFs.....	18
1.4 Structure and IGF Binding Determinants of the IGFBPs.....	20
1.4.1 Domain organization and disulfide bonds of IGFBPs.....	20
1.4.2 The IGF binding site on IGFBP N-domain .....	24
1.4.3 Structures of IGF·N-BP complexes .....	25
1.4.4 The IGF-binding site on IGFBP C-domain .....	26
1.4.5 The linker domain .....	29

1.5	Modifications and Other Molecular Interactions of IGFBPs .....	29
1.5.1	Proteolysis of IGFBPs .....	31
1.5.2	Post-translational modifications of IGFBPs .....	32
1.5.3	Heparin, glycosaminoglycan and extracellular matrix binding.....	33
1.5.4	Integrin binding .....	34
1.5.5	Other molecular interactions .....	35
1.6	Introduction to Protein Structure and Dynamics by NMR Spectroscopy .....	37
1.7	Aims and Strategy of the Present Work .....	42

## Chapter 2 Generation of Vectors for Recombinant Protein Expression..... 45

2.1	Introduction .....	45
2.2	Materials .....	48
2.2.1	Reagents and kits.....	48
2.2.2	Bacterial strains .....	48
2.2.3	Bacterial culture media.....	48
2.2.4	Solutions for DNA procedures .....	49
2.2.5	PCR primers .....	50
2.3	Methods .....	50
2.3.1	Amplification of DNA by PCR .....	50
2.3.2	Mini-preparation of plasmid DNA .....	52
2.3.3	Restriction endonuclease digestion of DNA .....	52
2.3.4	Agarose gel electrophoresis of DNA.....	52
2.3.5	Isolation and purification of DNA from agarose gel.....	53
2.3.6	Dephosphorylation .....	53
2.3.7	DNA Ligation.....	53
2.3.8	Preparation of competent cells .....	54
2.3.9	Transformation of bacterial cells.....	54
2.3.10	Screening of clones.....	54
2.3.11	DNA sequencing .....	55
2.4	Results and discussion .....	56
2.4.1	Wild-type IGFBP-2 constructs .....	56
2.4.2	IGFBP-2 (3C protease site at 183) construct.....	56
2.4.3	IGFBP-2 N-domain constructs .....	56

2.4.4	IGFBP-2 C-domain constructs .....	56
2.4.5	Results of DNA work .....	56

## Chapter 3 Preparation and Characterization of IGFBP-2 N- and C-terminal

Domains.....	65
3.1 Introduction .....	65
3.2 Materials .....	66
3.2.1 Reagents and kits.....	66
3.2.2 Bacterial strain.....	67
3.2.3 Minimal media for isotope-labelled protein expression.....	67
3.2.4 Nickel-IDA Chromatography buffers.....	68
3.2.5 IGF affinity column buffer .....	69
3.2.6 HPLC buffers.....	69
3.2.7 3C and TEV protease cleavage buffer.....	69
3.2.8 Buffers for protein electrophoresis .....	69
3.2.9 Buffers for cross-linking and BIAcore analysis .....	70
3.3 Methods .....	70
3.3.1 Expression of proteins in <i>E. coli</i> .....	70
3.3.2 Nickel-IDA chromatography.....	71
3.3.3 IGF affinity chromatography.....	72
3.3.4 Initial trials of 3C and TEV protease cleavage.....	72
3.3.5 3C protease cleavage .....	72
3.3.6 Preparative HPLC.....	73
3.3.7 SDS polyacrylamide gel electrophoresis and staining .....	73
3.3.8 Analytical HPLC and quantification of the protein.....	74
3.3.9 Mass Spectroscopy and N-terminal Sequencing .....	74
3.3.10 Cross-linking .....	74
3.3.11 Preparation of BIAcore biosensor surface.....	75
3.3.12 Acquisition and analysis of BIAcore data .....	75
3.4 Results .....	76
3.4.1 3C and TEV protease cleavage.....	76
3.4.2 Expression and purification of C-BP-2 and N-BP-2 .....	79
3.4.3 Mass Spectroscopy and N-terminal Sequencing .....	82

3.4.4	Cross-linking .....	90
3.4.5	BIAcore analysis .....	90
3.5	Discussion .....	98
3.5.1	Recombinant expression of IGFBP-2 fragments: the solubility issue	98
3.5.2	Purification of IGFBP-2 domains: the use of 3C and TEV proteases .....	100
3.5.3	IGF-binding by C-domain fragments .....	101

## Chapter 4 Solution Structure and Backbone Dynamics of the IGFBP-2 C-terminal

Domain .....	104	
4.1	Introduction .....	104
4.2	Materials and Methods .....	106
4.2.1	Materials .....	106
4.2.2	NMR spectroscopy experiments.....	106
4.2.3	Assignments .....	112
4.2.4	Distance constraints.....	112
4.2.5	Dihedral constraints.....	112
4.2.6	Hydrogen bond constraints.....	113
4.2.7	Structure calculations and refinement .....	113
4.2.8	Backbone <sup>15</sup> N relaxation parameters .....	113
4.2.9	Translational diffusion .....	114
4.2.10	Rotational motions .....	115
4.2.11	Reduced spectral density mapping .....	115
4.3	Results .....	116
4.3.1	NMR assignments and constraints .....	116
4.3.2	Solution Structure of C-BP-2 .....	121
4.3.3	Comparison with C-BP-1, C-BP-4, and C-BP-6 .....	130
4.3.4	<sup>15</sup> N relaxation parameters, overall rotational and translational motions .....	133
4.3.5	Backbone dynamics from reduced spectral density mapping .....	134
4.4	Discussion .....	139
4.4.1	Structural differences and implications for IGF binding and functional diversity .....	139

4.4.2	Structure and function of the RGD motif.....	141
4.4.3	Backbone flexibility of C-BP-2.....	142

## Chapter 5 Heparin Binding by the IGFBP-2 C-terminal Domain..... 145

5.1	Introduction .....	145
5.2	Materials and Methods .....	150
5.2.1	Materials .....	150
5.2.2	Methods .....	150
5.3	Results .....	150
5.3.1	Chemical shift perturbations.....	150
5.3.2	Effects of pH on the binding .....	153
5.3.3	The heparin binding site on C-BP-2.....	155
5.4	Discussion .....	155
5.4.1	Heparin binding by IGFBP-2 C-domain .....	155
5.4.2	The heparin binding site on C-BP-2.....	158
5.4.3	Implication for the role of C-BP-2 in cancer.....	160

## Chapter 6 NMR Spectroscopy of IGFs and IGFBP-2 N-terminal Domain..... 161

6.1	Introduction .....	161
6.2	Materials and Methods .....	162
6.2.1	Materials .....	162
6.2.2	NMR experiments and assignments for IGF-I .....	163
6.2.3	NMR experiments on IGF-II.....	163
6.2.4	NMR experiments on N-BP-2 .....	164
6.3	Results .....	164
6.3.1	NMR spectra of IGF-I .....	164
6.3.2	Assignments of the $^1\text{H}$ - $^{15}\text{N}$ HSQC spectra of IGF-I.....	165
6.3.3	Spectra of IGF-I in the absence and presence of heparin.....	168
6.3.4	NMR spectra of IGF-II.....	172
6.3.5	NMR spectra of N-BP-2.....	172
6.4	Discussion .....	175
6.4.1	NMR spectroscopy of IGF-I and IGF-II at lower protein concentration .....	175

6.4.2	NMR experimental conditions and assignments for IGF-I .....	175
6.4.3	NMR experimental conditions for IGF-II .....	176
6.4.4	NMR spectroscopy of N-BP-2 .....	177
6.4.5	Effects of heparin on IGF-I and N-BP-2 spectra.....	178

## Chapter 7 Binding Sites and Cooperativity of IGFBP-2 N- and C-terminal

Domains in IGF Binding .....	179
7.1 Introduction .....	179
7.2 Materials and Methods .....	180
7.2.1 Materials .....	180
7.2.2 NMR experiments on <sup>15</sup> N-labelled IGF-I and IGF-II.....	181
7.2.3 NMR experiments on <sup>15</sup> N-labelled C-BP-2.....	181
7.2.4 NMR experiments on <sup>15</sup> N-labelled N-BP-2 .....	181
7.3 Results .....	182
7.3.1 Binding of C-BP-2 to IGFs.....	182
7.3.2 Binding of N-BP-2 to IGFs .....	182
7.3.3 Binding of C-BP-2 to the IGF·N-BP-2 binary complexes .....	187
7.3.4 Interaction between N-BP-2 and C-BP-2 in the absence of IGFs....	191
7.3.5 Effects of heparin binding on IGF binding by N- and C-BP-2 .....	194
7.4 Discussion .....	197
7.4.1 Cooperativity between N- and C-BP-2 in IGF binding.....	197
7.4.2 Conformational change of IGF-I.....	199
7.4.3 Inter-domain interaction between N-BP-2 and C-BP-2 .....	202
7.4.4 Binding sites and effect of heparin binding.....	205

## Chapter 8 Final Discussion.....

8.1 Summary of Findings .....	209
8.2 Future Directions.....	213

References .....	216
------------------	-----

## Abstract

Insulin-like growth factor binding protein-2 (IGFBP-2) is the largest member of a family of six proteins (IGFBP-1 to 6) that bind insulin-like growth factors-I and -II (IGF-I/II) with high affinities. IGFBP molecules contain three domains of approximately equal length: the conserved cysteine-rich amino- and carboxyl-terminal domains, which are joined by a variable linker domain. The C-terminal domains of IGFBPs not only contribute to high-affinity IGF binding, but also confer binding specificity and have overlapping but variable interactions with many other molecules. At the time this project commenced, there was limited information on the structure-function relationships of the C-domain of IGFBPs.

In this thesis, the following N- and C-domain fragments were prepared in sufficient quantities for NMR studies: unlabelled,  $^{15}\text{N}$ -labelled and  $^{15}\text{N}/^{13}\text{C}$ -labelled  $^{183-289}\text{IGFBP-2}$  (C-BP-2), unlabelled  $^{141-289}\text{IGFBP-2}$  (Large-C-BP-2), and unlabelled and  $^{15}\text{N}$ -labelled  $^{1-138}\text{IGFBP-2}$  (N-BP-2). The IGF binding abilities of these fragments were assessed using BIAcore and cross-linking methods. Overall, the results indicated that C-BP-2 binds IGFs to only a limited extent, although the differences in IGF binding affinities among C-BP-2, N-BP-2 and full-length IGFBP-2 appeared to be larger in cross-linking studies than in BIAcore experiments.

The solution structure of C-BP-2 was determined using NMR spectroscopy. C-BP-2 has a thyroglobulin type 1 fold comprising an  $\alpha$ -helix, a three-stranded anti-parallel  $\beta$ -sheet and three flexible loops. Compared to the structures of C-BP-6 (Headey et al., 2004a), C-BP-1 (Sala et al., 2005) and C-BP-4 (Sitar et al., 2006), which were reported during the course of the current study, the following structural differences that may affect IGF binding and have implications for other functional differences were found: C-BP-2 has (i) a longer disordered loop I, and (ii) an extended C-terminal tail, which is unstructured and very mobile. (iii) The length of the helix is identical to that of C-BP-6 but shorter than that of C-BP-1. (iv) An RGD motif is located in a solvent-exposed turn. The backbone dynamics of C-BP-2 were analysed using the reduced spectral density mapping approach based on the measured backbone amide  $^{15}\text{N}$  relaxation parameters ( $R_1$ ,  $R_2$  and steady-state  $^{15}\text{N}$ - $\{^1\text{H}\}$  NOE), and the results were compared to the dynamic properties of C-BP-6 (Yao et al., 2004). C-BP-2 possesses significant fast time-scale



motions in the loops and termini, and may also have slow time-scale conformational or chemical exchange in the structured domain core and the loop II.

A more complete set of assignments for IGF-I  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectra was obtained. The IGF and N-BP-2 binding sites on C-BP-2 were identified by NMR. Binding of C-BP-2 to the IGF·N-BP-2 binary complexes was significantly stronger than the binding of C-BP-2 to IGFs alone, switching from intermediate exchange to slow exchange, indicating there is cooperativity between N-BP-2 and C-BP-2 in IGF binding. Two possible structural mechanisms for this cooperativity were found: a possible conformational change of the Phe49-Leu54 region and the sidechain aromatic ring of Phe49 in IGF-I, and direct interaction between the N- and C-domains.

A pH-dependent heparin binding site on C-BP-2 was also identified by NMR. The heparin binding site is a patch containing the  $\beta$ -turn connecting the first and second strands, part of the third strand, and the beginning of the C-terminal tail. Lys227, His228, Asn232, Leu233, Lys234 and His271 are proposed to be the primary heparin binding residues. Protonation of His271 and His228 seems to be important for the binding, which occurs at slightly acidic pH (6.0) and is more significant at pH 5.5, but is largely suppressed at pH 7.4. Possible preferential binding of IGFBP-2 and its C-domain fragments to glycosaminoglycans in the acidic extracellular matrix of tumours may be related to their roles in cancer.